Neuroimmune Dysregulation Underlying Comorbidity of Major Depressive Disorder and Migraine

Overview

This study integrates single-nucleus and bulk transcriptomic data to elucidate shared neuroimmune mechanisms in major depressive disorder (MDD) and migraine. It identifies common gene expression alterations in central nervous system glial cells and peripheral immune cells, highlighting dysregulated astrocytes, oligodendrocytes, and microglia as key contributors to their comorbidity.

Background

Major depressive disorder (MDD) is a highly prevalent psychiatric condition with significant cognitive and pain symptoms, disproportionately affecting women. Migraine, a neurological disorder characterized by severe headaches, also shows higher prevalence in women and frequently co-occurs with MDD. Genetic and clinical studies suggest overlapping pathophysiology, particularly involving neuroimmune dysfunction and glial cell dysregulation. Understanding shared molecular mechanisms is critical for improving treatment strategies for patients with comorbid MDD and migraine.

Data Highlights

Key Findings

• Astrocyte marker expression is significantly downregulated in MDD brain tissue without neuronal loss, distinguishing it from other neuropsychiatric disorders.
• Oligodendroglial lineage cells, including oligodendrocytes and their precursors, show core pathological dysregulation in MDD.
• Microglia and astrocyte overactivation promotes neuroexcitatory compound release, contributing to migraine pathogenesis.
• Patients with MDD have a 2- to 3-fold increased risk of migraine, and migraine patients have over a 3-fold increased risk of developing depression, indicating strong comorbidity.
• Shared transcriptional alterations in central nervous system glial cells and peripheral immune cells suggest bidirectional neuroimmune communication underlies MDD-migraine comorbidity.
• Integration of snRNA-seq and bulk transcriptomic data reveals common gene expression signatures and functional changes across brain and blood cell types in both disorders.

Clinical Implications

Recognition of neuroimmune dysregulation involving glial and immune cells in MDD and migraine highlights potential targets for therapeutic intervention. Clinicians should consider the high comorbidity and overlapping pathophysiology when diagnosing and managing patients presenting with either condition. Targeted treatments addressing astrocyte and microglial dysfunction may improve outcomes in comorbid cases.

Conclusion

This study provides molecular evidence that neuroimmune dysregulation and glial cell abnormalities form a shared pathological basis for the frequent comorbidity of MDD and migraine. These insights pave the way for developing precise, mechanism-based interventions targeting central and peripheral immune interactions.

References

1. Wang et al. 2023 -- Mechanisms of Comorbidity and Neuroimmune Dysregulation in Major Depressive Disorder and Migraine